Try our Advanced Search for more refined results

Expert Analysis

Does Indication-Specific Pricing Fit Generics With Carveouts?

By Michael Cottler and Natasha Daughtrey ( December 15, 2017, 12:03 PM EST) -- Indication-specific pricing (ISP) is often proposed as a solution to rising health care costs, particularly for branded drugs that have multiple indications. But it is unclear whether such a model could work with generic and biosimilar products that have labels from which one or more approved uses have been carved out. . . .

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections

Law Firms

Companies

Government Agencies